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GENERAL INTRODUCTION
   Diabetes mellitus is a group of metabolic diseases characterized by varying or persistent
hyperglycemia. Hyperglycemia in itself can lead to dehydration and ketoacidosis, and
prolonged hyperglycemia can lead to many serious complications, including cardiovascular
disease, chronic renal failure, retinal damage, nerve damage, and gangrene with risk of
amputation ofthe toes, feet and even the entire leg. According to a survey of World Health
Organization, today more than 170 million people worldwide suffer from diabetes, and its
incidence is on the increase at an alarming rate. Diabetes mellitus is one of the most
significant diseases in the developed world, and is the subject of increasing attention.
   Insulin, composed of 51 amino acids, is a key hormone regulating the blood glucose
level, and it is the mainstay of drug therapy for patients with insulin-dependent diabetes
mellitus. There are several types of insulin preparations, such as Regular, Lispro, NPH,
Lente and Ultra Lente, and they differ in characteristics, such as time of onset, peak activity,
and duration ofbiological action (i'2). Although the blood glucose level can be controlled by
these insulin preparations, they are all limited to the injection dosage form. The
subcutaneous injection of insulin has several disadvantages, including peripheral
hyperinsulinemia, hypoglycemia, and unacceptability due to the use of painfu1 and
troublesome injections.
   To this date, a variety of routes of administration (3'4), including dermal (5'6), nasal (7),
pulmonary (8'ii) and oral routes (i2'i3), have been investigated for their applicability, mainly in
order to reduce the pain associated with injection, and to improve the pharmacodynamic
properties of the applied insulin. In particular, a great deal of work has been focused on the
development of oral insulin delivery. Endogenous insulin is secreted by the pancreas into
tributaries of the hepatic portal vein, resulting in the direct delivery of insulin to the liver,
                                    -l-
which is the principal target organ of insulin and also removes halfof the insulin presented to
it in a single transhepatic circulation (i4). Oral insulin delivery is thought to be close to the
physiological state, since it offers a means of improving the portal levels of insulin, and also
curbs the peripheral hyperinsulinemia. However, most peptides, including insulin, are
poorly absorbed via the intestinal membrane because of extensive proteolytic degradation by
intestinal enzymes and their insuff7icient membrane permeability due to their high molecular
weight and low lipophilicity.
   Numerous strategies have been devised to improve the oral bioavailability of peptide
drugs. They include approaches regarding the development ofmultifunctional drug carriers
(i5-i7) and the co-administration of protease inhibitors andlor absorption enhancers (7'i8). A
water-in-oil-in-water (WIOIW) multiple emulsion (Fig. 1) is thought to be an efficient drug
carrier because it can protect the peptides against proteolysis (i9'20). In addition, the
emulsion system can incorporate various types of ingredients in each phase, in accordance
with its solubility. Several researchers have reported that the enteral bioavailability ofdrugs,
including peptides, was successfu11y promoted by using the WIOIW multiple emulsion
(i9•2i'22). previous studies in our laboratory have also documented that the intestinal
absorptions of peptide drugs, such as insulin and vancomycin, were improved by using this
system (23'26), and also found that the unsaturated fatty acids shown in Fig. 2, such as oleic
acid (OA, 18:1, n-9), eicosapentaenoic acid (EPA, 20:5, n-3) and docosahexaenoic acid
(DHA, 22:6, n-3), were effective in improving the insulin mucosal absorption following
co-administration (24'25). They have an advantage for use in pharrnaceuticals because they
are endogenous compounds present in mammalian cells and probably induce less toxicity
OA alters the membrane permeability by increasing the membrane fiuidity, and is often used
as a permeation enhancer (27'28). EPA and DHA are polyunsaturated fatty acids (PUFAs)
highly enriched in brain lipids and retinal photoreceptor cell phospholipids (29'30). It is well
-• 2-
known that the dietary intake of PUFAs is linked to the prevention of diseases, such as cancer
(3i'32) and heart disease (33-35), and is needed for neurological and brain development (36). The
various actions of PUFAs on biological functions have been paid attention in recent years.
Figure 1.
                    Inner aqueous phase
                     lnsulin solution with gelatin
                    0ilypkase
                     Phospholipids Span 80
                     Triolein Fatty acid
                     DL-a-tocopherol
                    Ou ter aqueous phase
                     Purified water containing 3 O/o Tween 80
Composition of W/OIW multiple emulsion system
Stearic acid (SA, 18:O)
Oleic acid (OA, 18:1, n-9)
Eicosapentaenoic acid (EPA, 20:5 n-3)
Docosahexaenoic acid (DHA, 22:6 n-3)
Figure 2. Chemical structure of fatty acids
   The aim of this study was to establish a novel insulin enteral delivery system using a
WIO/W multiple emulsion. In Chapter 1, the effectiveness and the toxicity ofPUFAs as a
potential absorption enhancer were investigated in in situ and in vivo insulin absorption
studies. In Chapter 2, in order to examine the action of unsaturated fatty acids on the lipid
bilayer, dipalmitoylphosphatidylcholine (DPPC) liposomes were used as a model ofthe lipid
                                    -3-
bilayer and the structural changes in the lipid bilayer induced by fatty acids were assessed by
measuring the changes in the phase transition temperature, fluorescence anisotropy, and
detergent insolubility. In Chapter 3, according to experimental design, the relationships
between causal factors and individual characteristics ofemulsion were identified. Moreover,
formulation optimization was canied out by means ofa novel optimization technique.
-
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              CHAPTER 1
Enhancement effect of polyunsaturated fatty acids
       on intestinal insulin absorption
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1. Introduction
   Extensive studies have been conducted in the intestinal absorption of peptides and
proteins, especially insulin. They generally exhibit poor absorption from the gastrointestinal
tract in the absence of an absorption modifying component, the so-called absorption enhancer
(7). In order to improve oral bioavailability of insulin, so far various kinds of absorption
enhancers, such as fatty acids, bile salts, surfactants and chelating agents, have been utilized
(18,37-39)
   In our laboratory, unsaturated fatty acids have been tested as an absorption enhancer for
intestinal insulin absorption, and their marked enhancement effects were observed in the in
situ loop experiments (24'25). These unsaturated fatty acids include 18-carbon fatty acids,
such as OA, linoleic acid (18:2) and linolenic acid (18:3), and PUFAs, such as DHA and EPA.
Particularly, the enhancement effects of PUFAs on insulin absorption in the rectum or colon
were more effective than those of 18-carbon unsaturated fatty acids (24).
   To further investigate the effectiveness and the toxicity of PUFAs as a potential
absorption enhancer for intestinal insulin absorption, in situ loop and in vivo absorption
experiments were accomplished. Firstly, the enhancement effects of various fatty acids
incorporated in insulin emulsion on rectal insulin absorption were determined. The
site-dependency and the reversibility of the effect of DHA on intestinal insulin absorption
were also assessed. Considering the clinical use of insulin preparations, multiple
administrations of the insulin emulsion were performed, and the change in the hypoglycemic
effect and mucosal damage induced by the emulsions were examined. In order to control
the duration of hypoglycemic effect of the formulation, insulin emulsion containing Pluronic
F127 (PF127), gel forming block copolymer, was prepared and its effect on the time profiles
ofthe serum glucose level was evaluated.
-
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2. MaterialsandMethods
2.1. Materials
   Crystalline porcine insulin (27.3 IU/mg) was supplied by Simizu Phamiaceutical Co.,
Ltd. (Shizuoka, Japan). Lauric acid (purity: 99.0 O/o), gelatin, glucose B-Test kit, triolein,
sorbitan monooleate (Span 80) and DL-ct-tocopherol were purchased from Wako Pure
Chemical Industries, Ltd. (Osaka, Japan). Capric acid (purity: 99.0 O/o), glycocholic acid
(purity: 97.0 O/o), SA (purity: 99.0 O/o) and PF127 were purchased from Sigma Chemical Co.,
Ltd. (St. Louis, MO, USA). Polyoxyethylene sorbitan monooleate (Tween 80) and OA
(purity: 99.0 O/o) were purchased from Tokyo Kasei Kogyo Co., Ltd. (Tokyo, Japan). Egg
yolk phospholipids (phosphatidylcholine and phosphatidylethanolamine) were purchased
from Nippon Oil & Fats Co., Ltd. (Tokyo, Japan). DHA (purity: 99.0 O/o), EPA (purity:
99.0 O/o), docosahexaenoic acid 2-monoglyceride (DHA-MG, purity: 30.0 O/o) and
docosahexaenoic acid triglyceride (DHA-Tq purity: 30.0 O/o) were provided by Nippon
Suisan Kaisya Ltd. (Tokyo, Japan). All other chemicals were ofanalytical grade.
22. PreparationofW/O/VVmultipleemulsion
   Insulin emulsions were prepared by a two-step emulsification procedure using a
homogenizer (Ace Homogenizer, Nihonseiki Kaisha Ltd., Tokyo, Japan) according to a
method reported in a previous paper (24). Designated amounts of insulin were dissolved in
200 pL of O.1 N HCI, and then phosphate-buffered saline (PBS, pH 7.4) containing gelatin
(5 O/o of the inner aqueous phase) was added to the solution. The pH value ofthe solutions
was adjusted to pH 7.4 by the addition ofO.1 N NaOH as required. The weight was finally
adjusted to 2 g, and this solution used for the inner aqueous phase. The concentrations of
each component in the oily phase were as follows: DL-or-tocopherol, O.06 O/o; egg yolk
phospholipids (phosphatidylcholine: phosphatidylethanolamine, 7:3), 5 O/o; Span 80, 20 O/o.
-
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Free or glycerides of fatty acids were also added to the oily phase, and the concentration was
fixed at O, O.5, 1, 2 or 5 O/o of the total weight of the emulsion. An appropriate amount of
triolein was added to adjust the weight ofthe oily phase, and 8 g ofthe oily phase was finally
yielded. The inner aqueous phase was added to the oily phase, and then the first
emulsification was canied out to form WIO emulsion using the homogenizer. Thirty grams
of purified water containing 3 O/o Tween 80 was used for the outer aqueous phase. After
addition of the primary W!O emulsion to the outer aqueous phase, the second emulsification
was performed to form the W/O/W multiple emulsion. The weight ratio of each phase was,
inner aqueous phase: oily phase: outer aqueous phase, 1 :4:15.
   As for the insulin emulsion containing PF 127, firstly, an insulin emulsion containing
DHA (weight ratio of inner aqueous phase: oily phase: outer aqueous phase, 1:4:5) was
prepared in the same way as described above. A stock PF 127 solution was prepared by
dissolving designated amounts of PF 127 in purified water on ice, and kept at 5-10 OC to
avoid gelation. Cold insulin emulsions were gently added to the PF 127 solution at a weight
ratio of 1 to 1, and then the mixture was stirred until it became homogeneous. The final
concentrations ofPF 127 and DHA were fixed at 15 and 2 O/o ofthe total weight, respectively.
2.3. In situ absorption experiments
   All the animal studies were performed in compliance with the regulations of the
Committee on Ethics in the Care and Use of Laboratory Animals at Hoshi University. Male
Wistar rats weighing 180-220 g were purchased from Tokyo Laboratory Animal Science Co.,
Ltd. (Tokyo, Japan). The animals were housed in environmentally controlled rooms at 23 Å}
1 OC and 55 Å} 5 O/o relative humidity, and allowed free access to water and food during
acclimatization. The rats were fasted for 48 h prior to the experiments. Following
anesthetization with an i.p. injection of 50 mglkg sodium pentobarbital (Dainippon
-
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Pharmaceutical Co., Ltd., Osaka, Japan), the rats were restrained in a supine position on a
thermostatically controlled board at 37 OC. A 5 cm loop of the ileum, the colon or the
rectum was identified and ligated at both ends. The ileal loop was made at the neighboring
part of the cecum, and the colonic loop was made at the ascending colon. Subsequently,
they were carefu11y returned to their original location inside the peritoneal cavity. The rats
were further left on the board at 37 OC for 1 h to recover from the elevated blood glucose
level due to the surgical operation. Insulin solution or insulin emulsion was administered
directly into each loop through a stomach sonde needle for rats (KN-348, Natsume
Seisakusyo Ltd., Tokyo, Japan). The insulin doses were 10, 20 and 50 IUIkg body weight,
and the doses of insulin were changed by adjusting the amount of emulsion. A O.2 mL
sample of blood was taken from the jugular vein 5 min before the administration.
Subsequent blood samples were taken at specified periods after dosing. Serum was
separated by centrifugation at 13,400xg for 1 min and kept at -20 OC until analysis. The
serum glucose level was determined using a glucose B-Test kit. Post-dose levels of the
serum glucose were expressed as a percentage of the pre-dose level. The percentage change
in the serum glucose levels was taken as the percentage of the pre-dose level subtracted from
100. The cumulative percentage change in the serum glucose level was calculated by
summing, using the trapezoidal method, the areas below the baseline levels in the percentage
change versus time curves for O-4 h (the area above the glucose level-time curve: AACgiucose).
The pharmacological availability was calculated according to the method described by
Morishita et al (26). Insulin PBS solutions were administered subcutaneously at doses ofO.5,
1.0, 2.0 and 3.0 IUIkg body weight. Blood samples were collected from thejugular vein at
designated periods. AACgiuco,, values were obtained, and then the dose-response curve
between the logarithm of s.c. insulin doses and AACgiu,.se was estimated. The
pharmacological availability, the relative bioavailability compared to s.c. route, was
-
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calculated using the dose-response curve.
   Insulin absorption was further studied in the same in situ system, but using the rectal
segments pretreated with insulin free emulsion. This study was designed to evaluate the
reversibility ofthe emulsion's insulin absorption enhancement effects. The WIOIW multiple
emulsions containing 2 O/o capric acid and DHA, and 3 O/o glycocholic acid PBS solution
(positive control) were used as the test solutions. The rectal loop was exposed to O.5 mL of
test solution for O.5 or 3 h. Following exposure, the loop was gently rinsed with 20 mL of
warmed PBS, and subsequently O.5 mL of insulin PBS solution was administered to the loop
at a dose of 1O IUIkg body weight, and the in situ insulin absorption studies were performed.
Each mean value of AACgiucose was calculated. The reversibility was calculated as the
percent change in the AACgiucose value as follows. The percent change in the AACgiucose
value == AACgiucose of insulin solution after the exposure of insulin free emulsion 1 AACgiucose
of insulin emulsion containing fatty acid Å~ 100. In the case of glycocholic acid, the
AACgiucose of the insulin solution was divided by the AACgi.,.,, of the co-administration of
insulin and glycocholic acid.
2.4. In vivo single and multiple absorption experiments
   Male Wistar rats weighing 180-220 g were purchased from Sankyo Labo Service Co.,
(Tokyo, Japan). The rats were fasted for 48 h prior to the experiments. In the case of
experiments using insulin emulsion as the dosage form, rats were housed in cages and were
given water ad libitum, except for at the time of administration and blood sampling during the
experimental periods. The rats were restrained in a supine position during administration
and at each blood sampling under non-anesthesia. On the other hand, in the case of
experiments using an insulin emulsion containing PF 127 hydrogel, the rats were anesthetized
with the i.p. injection of 50 mg!kg sodium pentobarbital, and restrained in a supine position
-
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throughout the experiment on a thermostatically controlled board at 37 OC. Insulin
emulsions were administered rectally through the stomach sonde needle for rats. The
insulin doses were 5, 10 and 20 IUIkg body weight. The blood samples were withdrawn at
designated periods, and the determination of the serum glucose levels was performed as
described above. In addition, the serum insulin levels were determined using enzyme
immunoassay (IMX System, Abbott Japan Co., Ltd., Tokyo, Japan). The basal endogenous
insulin level was subtracted from all insulin levels measured following insulin administration.
The area under the insulin level-time curves for O-4 h (AUCinsuiin) was determined using the
trapezoidal method.
   As for the multiple administration experiments, each emulsion was rectally administered
once a day at 10:OO a.m. for 1O days. The dose of insulin was fixed at 5 IUIkg body weight.
On the first and tenth day, the in vivo insulin absorption experiments were performed.
Immediately after the absorption experiment on the tenth day, the rectums were excised to
evaluate their mucosal damage. The isolated intestines were fixed in 10 O/o neutral
carbonate-buffered formalin, paraffin-sectioned, and stained with hematoxylin and eosin.
All tissues were analyzed using light microscopy and scored based on the histopathological
findings.
-
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3. ResultsandDiscussion
3.1. Enhancement effect of unsaturated fatty acids contained in insulin emulsion on
rectal insulin absorption
   Figures 3 and 4 show the changes in the serum insulin and glucose levels following the
rectal administration of insulin emulsions containing various fatty acids in the in vivo
absorption study. The concentration of fatty acids contained in the emulsion was fixed at
2 O/o of the total weight, and the insulin dose was 5 or 10 IU!kg. An insulin emulsion
containing SA, 18-carbon saturated fatty acid, was used as a control. As shown in Figs. 3
and 4, the rectal insulin absorption was improved markedly, and a marked hypoglycemic
effect was induced by the administration of insulin emulsions containing unsaturated fatty
acids, such as OA, EPA and DHA. The peak insulin levels and the lowest glucose levels
appeared at O.25-O.5 and O.5 h after administration, respectively. The increase in the insulin
level and the reduction in the serum glucose level were progressively pronounced with the
increase in the insulin dose.
 2ooo (a) 2ooo (b) 2ooo (c)
--
-
    O 1 2 3 4 O 1 2 3 4 Q1 2 3 4
            Time (h) Time (h) Time (h}
Figure 3. Change in serum insulin level following the rectal administration of insulin
emulsion containing 2 O/o (a) OA, (b) EPA and (c) DHA. Each value represents the mean Å}
S.D. of five to seven rats.
Key: (-) 5 IU/kg of insulin emulsion containing stearic acid (control); (e) S and (o) 1O IUIkg
of insulin emulsion, respectively.
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Figure 4. Change in serum glucose level following the rectal administration of insulin
emulsion containing 2 O/o (a) OA, (b) EPA and (c) DHA. Each value represents the mean Å}
S.D. of five to seven rats.
Key: (i) 5 IUIkg of insulin emulsion containing stearic acid (control); (e) 5 and (o) 10 IUIkg
of insulin emulsion, respectively.
Following these results, the values of AACgi.co,, were calculated. It was clearly observed
that the hypoglycemic effects were in an insulin dose related manner (Fig. 5). Notably,
significant relationships were shown between the insulin dose and AACgiucose after the
administration of the insulin emulsion containing EPA and DHA.
                          E250 E250E250
-
 y=7.52x+22.89 ' y=12.64x-".35 ' y=19,99x-7,77tr 2oo r= o.417 tr 2oo r= o.67s g2oo r= o,s34
2t•lso 2tlso pÅqo.o2 ts•lso pÅqo,oos
-
                          ouo
       tnsulin dose (tUikg) tnsutin dose (tU/kg) tnsutin dose (tUlkg)
 Figure 5. Relationship between insulin dose and AACgi.,.se following the rectal
 administration of insulin emulsion containing 2 O/o (a) OA, (b) EPA and (c) DHA. Each
 value represents the mean Å} S.D. of five to seven rats.
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The values for AACgiucose and the pharmacological availability are summarized in Table 1.
The values of pharmacological availability induced by the emulsion containing DHA and
EPA were greater than that of the emulsion containing OA. These results coincided with
those obtained from the previous in situ studies (24•26).
Table 1. Pharmacological
fatty acids
availability of insulin emulsion incorporating unsaturated
AACgiucose (O/o glu. reduc.' h) Pharmacological
availability (O/o)
OA
EPA
DHA
 92.3 Å}
116.6 Å}
193.7 Å}
44.4
61.6
63.8
 7.7 Å}
11.0 Å}
25.4 Å}
 3.3
 7.0
17.0
Insulin emulsions were administered rectally at 1O IUIkg of
Each value represents the mean Å} S.D. of five to seven rats.
insulin.
   Further, the dose-dependent effect of DHA was evaluated by assessing the values of
AUCinsuiin and AACgiucose after the rectal administration of insulin emulsions containing
various concentrations of DHA. The insulin dose was fixed at 5 IUIkg. These values
increased with the increase in the DHA concentration in the range of up to 1 O/o, and they
reached saturation point at over 1 O/o (Fig. 6). Considering the previous findings that
18-carbon unsaturated fatty acids did not promote the insulin absorption from the intestine at
1 O/o (26), DHA will be expected to enhance insulin absorption at smaller amounts than
18-carbon unsaturated fatty acids.
-
14-
Arpt
E
.E,
s
i
 E-
g
 .E
oD(
500
400
300
200
1OO
  o
(a)
  150
=-
s
6
=V
..100
j
'a
er
v:Åqe
$ 50g
e
aoÅq
Åq
(b)
                                       o
          O.5 1.0 2.0 5.0 O.5 1.0 2,O 5.0
            DHA concentration (O/o) DHA concentration (O/o)
Figure 6. Comparison of (a) AUCinsuiin and (b) AACgi.cose following the rectal administration
of insulin emulsion containing various concentrations of DHA (5 IUIkg). Each value
represents the mean Å} S.D. ofthree to four rats.
   As well as free fatty acids, it was reported previously that monoglyceride has an
enhancement effect on intestinal absorption of several drugs (38'42). sekine et al. reported
that the rectal absorption of cefmetazole sodium was promoted by the co-administration of
medium chain fatty acid monoglycerides (42). Based on these findings, the enhancement
effects of glycerides of DHA were evaluated. Figure 7 shows the hypoglycemic effects
following the in situ rectal administration of the emulsion containing glycerides of DHA, and
Table 2 lists the values of AACgiucose and pharmacological availability. The administration
of the emulsion containing DHA-TG (20 IUIkg) did not induce any hypoglycemic effect.
Small decreases in the serum glucose levels following the administration of the insulin
emulsion containing DHA-MG (20 IUfkg) were observed, and the lowest glucose level was
approximately 90 O/o of the initial level. Meanwhile, a marked hypoglycemic effect was
shown after the administration of the insulin emulsion containing DHA, despite a lower
insulin dose (1O IUIkg).
-
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Figure 7. Change in serum glucose level following the in situ rectal administration of insulin
emulsion containing 2 O/o glycerides ofDHA. Each value represents the mean Å} S.D. of five
to nme rats.
Key: (o) 50 IU!kg of insulin solution (control); insulin emulsion containing (A) DHA-TG
(20 IUIkg of insulin); (i) DHA-MG (20 IUIkg of insulin); (o) DHA (1O IUIkg of insulin).
Table 2. Phamiacological availability of insulin emulsion containing glycerides ofDHA
Fatty acid
Insulin dose
  (IUIkg)
   AACglucose
(O/o glu. reduc.' h)
Pharmacological
 availability (O/o)
DHA
DHA•-MG
DHA-TG
10
20
20
247.4 Å} 254.6
 37.4 Å} 16.4
 10.0 Å} L7
29.0 Å} 29.9
 1.6 Å} O.7a
 1.2 Å} O.2a
Each value represents the mean Å} S.D. of five to nine rats.
apÅq o.Os, vs DHA.
According to the results, the insulin absorption enhancement efficacies among various forms
of DHA were in the order of DHA-TG S DHA-MG ÅqÅq DHA. In general, dietary fats (År
90 O/o) exist as triglycerides in nature, and they are absorbed after digestion by pancreatic
lipase. The pancreatic lipase system attacks the triglyceride with a high degree ofpositional
specificity. Lipolysis occurs predominantly at the sn-1 and sn-3 positions, yielding two free
-
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fatty acids and a 2-monoglyceride (43). PUFAs and their 2-monoglyceride form are known
to be easily absorbed from the intestinal membrane (43). Taken together, it is likely that the
absorbability of fatty acids is related to their enhancement effects on insulin absorption.
3.2. Comparison of the enhancement effect of DHA on insulin absorption with those of
medium chain fatty acids
   Capric acid and lauric acid are medium chain fatty acids having 10 and 12 carbon alkyl
chains, respectively. Several studies have demonstrated that these fatty acids regulate the
permeability of Caco-2 monolayers and the intestinal epithelium, and enhance the absorption
of hydrophilic markers, such as sodium fluorescein (40'4i). This study compared the
enhancement effects of long chain unsaturated fatty acids on the intestinal insulin absorption
with those of medium chain fatty acids. Figure 8 shows the changes in the serum glucose
level following the in situ administration ofthe emulsions (1O IUIkg) containing various fatty
acids into the rectal loop. Insulin PBS solution (50 IUIkg) was used as a control. As
shown in Fig. 8, all the emulsions containing fatty acids induced marked hypoglycemic
effects, with the lowest glucose levels appearing 1-2 h after the administration. The
hypoglycemic effects induced by the emulsions containing EPA and DHA were pronounced
(Figs. 8 d and e). Table 3 shows the very high pharmacological availability of the insulin
emulsion containing DHA, and the values were significantly higher than those obtained from
the emulsion containing medium chain fatty acids.
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Figure 8. Change in serum glucose level following the in situ rectal administration of insulin
emulsion containing 2 O/o (a) capric acid, (b) lauric acid, (c) OA, (d) EPA and (e) DHA. Each
value represents the mean Å} S.D. of five to nine rats.
Key: (o) 50 IUIkg of insulin solution (control); (e) 10 IUIkg of insulin emulsion,
respectively.
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Table 3. Pharmacological availability of insulin emulsion containing various fatty acids
Fatty acid
   t()LACglucose
(O/o glu. reduc.' h)
Pharmacological
 availability (O/o)
Capric acid
Lauric acid
OA
EPA
DHA
 68.2 Å}
 50.8 Å}
 56.3 Å}
153.6 Å}
247.4 Å}
 79.0
 25.3
 15.6
133.9
254.6
 4.4 Å}
 3.7 Å}
 3.9 Å}
10.8 Å}
29.0 Å}
 5.la
 1.sa
 1.la
 9.5
29.9
Insulin emulsions were administered into rectal loop at 1O IUIkg of insulin.
Each value represents the mean Å} S.D. of four to nine rats. apÅq O.05, vs DHA.
3.3. Site-dependenthypoglycemieeffectoftheemulsioncontainingDHA
   There are many reports that absorption enhancers act more strongly in the large intestine
than in the small intestine (39'44'45). previous studies in our laboratory also documented that
insulin absorption from emulsions containing 18-carbon unsaturated fatty acids occurred site
dependently, and more markedly in the lower parts of the gastrointestinal tract, such as the
colon and rectum (24'25). This study evaluated the site-dependent enhancement effect of
DHA on intestinal insulin absorption. Figure 9 shows the changes in the serum glucose
level-time profiles following the in situ administration of the insulin emulsions (50 IUIkg)
containing DHA into the ileum, the colon and the rectum. The enhancement effect ofDHA
on insulin absorption was shown in all loops, and the effects in the colon and rectum were
stronger than in the ileum. The effect ofDHA was similar to those of 18-carbon unsaturated
fatty acids. These site-dependent effect is probably related to differences in the biological
functions ofthe intestinal tract and physical propenies ofthe mucosal membrane, such as the
composition of lipids and membrane fluidity (i8'38'46'47). In addition, it is known that the
activity of the proteases in the large intestine is lower than that in the small intestine (37'48),
and this contributes to the site-dependent effect to a certain extent. As the results of this
-
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study, it was confimied that the lar
this carrier system.
ge intestine was a suitable site for insulin delivery using
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Figure 9. Change in serum glucose level following the in situ administration of insulin
emulsion into various intestinal loops. Insulin emulsion containing 2 O/o DHA was
administered at 50 IUIkg ofinsulin. Each value represents the mean Å} S.D. of four to seven
rats.
Key: (A) intra-ileal; (i) -colonic; (e) -rectal administration ofthe emulsion.
3.4. Reversibility ofthe absorption modifying effect ofthe emulsions
   The changes in the AACgiucose values following pretreatment with insulin free emulsions
containing capric acid and DHA, and glycocholic acid solution are shown in Table 4.
Glycocholic acid, the major bile acid in humans, was used as a positive control. There are a
number of reports that bile acids and bile salts increase intestinal drug absorption by altering
the functions of the mucosal membrane (49-52). As shown in Table 4, in the case of
glycocholic acid, there was no significant reduction in the AACgiucose values between the O.5 h
pretreatment group and the co-administration group, with the enhancement effect on insulin
                                    -20-
absorption remaining. Since it is well known that the application of bile acids induces
mucosal damages (53'56), the continuance of the enhancement effect was probably due to the
mucosal damage caused by treatment with glycocholic acid. In addition, when the
pretreatment with glycocholic acid solution was prolonged to 3.0 h, the value of AACgiucose
markedly decreased. The reduction ofthe enhancement effect may be attributed to running
out ofthe administered glycocholic acid. Swenson et al. reported the intestinal wall damage
caused by bile salt treatment recovered to the control level within 3 h of the c'essation (56).
On the other hand, a marked reduction in the values of AACgiuÅëose was observed by the
pretreatment with the emulsion containing DHA and capric acid for O.5 h, and their
enhancement effects were diminished rapidly. Therefore, it was suggested that the action of
DHA on the intestinal membrane occurred temporarily and was highly reversible, and the
co-administration with insulin and DHA is necessary for improvement of intestinal insulin
absorption.
Table 4, Effect of the emulsion pretreatment on rectal insul in a bsorption
Sample
Pretreatment
 period (h)
Percent change in
AACglucose value
WIOIW multiple emulsion
  containing capric acid
WIOIW multiple emulsion
    containing DHA
Glycocholic acid solution
O.5
3.0
O.5
3.0
O.5
3.0
100.0 Å}
 22.1 Å}
 31.8 Å}
100.0 Å}
 20.5 Å}
 16.8 Å}
100.0 Å}
 73.2 Å}
 17.2 Å}
43 .4
24.3
27.3
10.0
 2,5
 1.4
20.7
44.3
15.1
Each value represents the mean Å} S.D.
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3.5. Hypoglycemic effect and toxicity induced by the multiple administrations of
insulin emulsion
   Multiple rectal administrations of insulin emulsions containing various fatty acids for 1O
days were performed, and the hypoglycemic effects were examined. Figure 10 shows the
time profiles of the serum glucose level following the administration of insulin emulsions
containing OA and DHA on the first or tenth day. Insulin emulsion without unsaturated
fatty acids was used as a control in this study. As for the emulsion containing DHA, a
marked hypoglycemic effect was observed after the multiple applications, and the AACgiucose
values on the first and the tenth day were almost the same. Although the AACgiucose values
did not change during multiple administrations, the minimal glucose level tended to decrease.
Similar trends were observed for the emulsion containing OA.
E
M
    O 1 2 3 4 O t 2 3 4 O 1 2 3 4
           Time (h) Time (h) Time (h)
 Figure 1O. Time profiles of serum glucose level following 1O days multiple administrations of
 insulin emulsion (a) without fatty acid (control) and containing 2 O/o (b) OA, or (c) DHA.
 Insulin emulsions were administered rectally at 5 IUIkg of insulin. Each value represents
 the mean Å} S.D. offive rats.
 Key: (e) First day, and (o) tenth day ofmultiple applications.
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   Moreover, the rectal mucosal damage following the multiple applications of insulin
emulsions was investigated. Light micrographs of the rectal mucosa following the multiple
applications of the emulsions are shown in Fig. 11, and tissue damage scores based on the
histopathological findings are summarized in Table 5. Multiple applications of insulin
emulsions containing DHA and OA induced no or very slight mucosal damage in the rectum.
         'Since these fatty acids are contained in natural sources and are usually obtained through diet,
their applications would not be accompanied by mucosal damage. Additionally, Horie et al.
reported that PUFAs, such as DHA, protected the small intestine from the mucosal damage
caused by the oral administration ofthe antitumor drug, methotrexate (57). Therefore, these
fatty acids can be safely used as absorption enhancers.
(a) (b)
f esN.tut't'  t
1.lt. .. {.. "
-..sza/tige.3-•
(c)
 ..y-  ..;;.,I.g. ..'
-tij
Figure ll. Light micrographs , mucosa following lO
multiple applications of insulin emulsion (a) without fatty acid and containing (b) OA,
(c) DHA.
days
and
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Table 5. Microscopical findings of the rectum following
applications of insulin emulsion containing fatty acids
10 days multiple
Microscopic fin dings
Fatty acid
Controla OA DHA
Mucosa
  Degeneration
Lamina propria mucosa
  Cellular infiltration
  Fibrosis
Submucosa
  Edema
  Cellular infiltration
o
o
o
o
o
o
o
o
o
o
1
1
o
o
o
Score: O, no change; 1, very slight; 2, slight; 3, moderate; 4, marked.
Insulin emulsions were administered rectally at 5 IUIkg ofinsulin.
aWIOIW multiple emulsion without fatty acids
3.6. Effect of PF 127 hydrogel on the hypoglycemic profiles of insulin emulsion
   To control the release profile of insulin from the emulsion, an insulin emulsion
containing PF 127 hydrogel was prepared, and its hypoglycemic effect was examined. As
shovvn in Fig. 12, marked and rapid reduction in the serum glucose level occurred due to the
administration of the insulin emulsion and the reduction recovered to the base-line within 4 h
after the administration. In contrast, a gradual decrease in the serum glucose level was
observed following the administration of insulin emulsion containing PF 127 hydrogel, and
was maintained up to 6 h after the administration. The nadir of the serum glucose-time
curve was broadened.
    The time profile ofthe glucose reduction provided by the insulin emulsion was similar to
that of the only insulin monomeric analogue, insulin Lispro (58). It was reported that the
pharmacokinetic and pharmacodynamic profiles of insulin Lispro closely mimic those of
-
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-                 Time (h} Time (h)
Figure 12. Effect of Pluronic F127 hydrogel contained in the emulsion on time profiles of the
serum glucose level. The formulation was administered rectally at (a) 5 or (b) 20 IUIkg of
insulin. Each value represents the mean Å} S.D. offour to six rats.
Key: (o) Insulin emulsion containing 2 O/o DHA, (o) insulin emulsion containing 2 O/o DHA
and PF127 hydrogel.
physiological mealtime insulin (2). In addition to the rapid-acting formulation, long-acting
formulations are required in order to generate basal insulin levels. The gel formulation has
the advantage of sustained drug release because of its adhesiveness and prolongation effect of
the contact time to the mucosal membrane. Kimura et al. reported that gel spheres
containing insulin prolonged the residence time in the small intestine (59). Thus, in order to
control the insulin release, a gel formulation that combined an insulin emulsion with a PF 127
hydrogel was prepared. PF127 is a block copolymer composed ofpoly(ethylene oxide) and
poly(propylene oxide), and can form micelles in water. Moderately concentrated solution of
PF127 in water exists as liquid at refrigerator temperatures and hydrogel at physiological
temperatures. PF127 hydrogel has generated considerable interest for drug delivery
applications because it enables the rapid conversion of a solution into a hydrogel after
administration into the body cavity. Barichello et al. evaluated PF127 hydrogel containing
-
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insulin and concluded that these formulations were usefu1 for the preparation of a controlled
delivery system (60). Figure 12 clearly shows that a prolonged hypoglycemic effect was
induced by an insulin emulsion containing PF 127 hydrogel. These results suggested that
insulin emulsion possesses the capacity for varying the drug release by using the PF 127
hydrogel.
-
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4. Conclusions
   To investigate the possibility of PUFAs as absorption enhancers for intestinal insulin
delivery, the effectiveness and the toxicity were evaluated with an in vivo and in situ study.
Marked insulin absorption and a hypoglycemic effect were shown within a very short time
after the rectal administration of insulin emulsion containing unsaturated fatty acids. The
hypoglycemic effects were in an insulin dose related manner. The enhancement effects of
PUFAs, in particular DHA, were much more pronounced than that of oleic acid, and reached
saturation point at 1 O/o ofthe total amount ofemulsion. The effect ofDHA was outstanding
compared to that of its glyceride forms or medium chain fatty acids. In addition, the effect
of DHA was site-dependent, and the action of DHA in the large intestine, such as the colon
and rectum, was stronger than in the small intestine, such as the ileum. Considering the
clinical use of insulin preparations, a multiple administration study was conducted. During
the multiple rectal applications of the insulin emulsion to rats for 1O days, the hypoglycemic
effects were successfully obtained, and no or very slight mucosal damage was observed in the
excised rectum. Moreover, to manipulate the glucose reduction profile, a gel formulation
that combined the insulin emulsion with PF127 hydrogel was prepared, and the
hypoglycemic effect was evaluated. As expected, the sustained hypoglycemic effect was
shown by the administration ofthis gel formulation.
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                    CHAPTER 2
Structural change in lipid bilayer induced by the treatment with
                       fatty acids
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1. Introduction
   In Chapter 1, it was confirmed that PUFAs, particularly DHA, had strong enhancement
effects on intestinal insulin absorption. These effects occurred within very short time after
administration, and the action was reversible without tissue damage. Although the
mechanism responsible remains unclear, the previous study in our laboratory suggested that
the effect ofPUFAs was attributed to their actions on the transcellular pathway rather than the
paracellular pathway because the tissue membrane resistance values did not change with
treatment (25). When an emulsion is administered into the intestinal lumen, the fatty acids
contained in the emulsion will be taken up readily into the lipid bilayer of the intestinal
mucosa, causing a change in the lipid packing. In general, the structural change in the lipid
bilayer is a critical factor for the transcellular pathway. There are many reports that
perturbation of the lipid-packing order increases drug permeability (27'29'6i). In addition,
recent studies have shown that altering membrane fluidity influences carrier-mediated
transport, such as P-glycoprotein-mediated efflux (62'64). Because DHA and EPA have
multiple double bonds, they should change the lipid packing drastically. Such changes in
the lipid bilayer structure should cause modifications of the biological membrane function,
and it is important to identify the action of fatty acids on the lipid bilayer structure.
    This Chapter investigated changes in the physical properties of the lipid bilayer by
treating model bilayer with various fatty acids, such as SA, OA, EPA, and DHA. Because
the plasma membrane structure is too complex, DPPC liposomes were used as a model of the
lipid bilayer. The structural changes in the lipid bilayer induced by fatty acids were assessed
by measuring changes in the phase transition temperature, fluorescence anisotropy, and
detergent insolubility. To evaluate whether fatty acids incorporated in the formulation act
successfu11y on the lipid bilayer, the same experiments were also performed using a WIOIW
multiple emulsion containing fatty acids.
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2. MaterialsandMethods
2.1. Materials
   Gelatin, triolein, Span 80, DL-ct-tocopherol, OA, Tween 80, egg yolk phospholipids
(phosphatidylcholine and phosphatidylethanolamine), DHA and EPA were the same as those
described in Chapter 1. DPPC, SA, polyoxyethylene (10) octylphenyl ether (Triton X-100),
phospholipid C-Test kit, and nonesterified fatty acid (NEFA) C-Test kit were purchased from
Wako Pure Chemical Industries, Ltd. (Osaka, Japan). 1,6-Diphenyl-1,3,5-hexatriene (DPH)
was purchased from Aldrich Chemical Co. (Milwaukee, WI). All other chemicals were of
analytical grade and commercially available.
2.2. PreparationofDPPCliposomes
   DPPC dissolved in chloroform was pipetted into a flask, and the chloroform removed by
evaporation at room temperature under a nitrogen stream. This procedure resulted in the
formation ofa thin lipid film on the inside wall ofthe flask. The film was stored ovemight
in a vacuum desiccator to ensure the complete evaporation of chloroform. Ten milliliters of
PBS was added to the flask and the DPPC was hydrated for 30 min. The suspension was
sonicated for 10 min at about 60 OC using a bath-type sonicator. The liposome suspension
was prepared at a total lipid concentration of 10 mM and stored at room temperature until
used in the experiments.
2.3. Differentialscanningcalorimetermeasurement
   Fatty acid suspensions and WIOIW multiple emulsions containing fatty acids were used
as the treatment solutions. Fatty acid suspensions were prepared by suspending designated
amounts of fatty acids, such as SA, OA, EPA, and DHA, in a mixture of methanol and PBS
(1:1, vlv). WIOIW multiple emulsions were prepared according to the method described in
-
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Chapter 1. The concentration of fatty acid was fixed at 2 O/o of total weight of emulsion.
The weight ratio of each phase was, inner aqueous phase: oily phase: outer aqueous phase,
1:4:15.
   Fatty acids were applied to the DPPC bilayer as described by Maitani et al (65). Two
hundred and fifty microliters oftreatment solution was added to 1000 pL ofDPPC liposome
suspensions and this mixture was incubated for 2 h at 37 OC. Samples were centrifuged at
13,400xg for 2 min to separate the supernatant and pellet. The obtained pellets of known
weight (approximately 5 mg) were placed in aluminum pans for the differential scanning
calorimeter (DSC) measurement. DSC measurements were performed with a Thermo Plus
DSC 8230 (Rigaku Co. Ltd., Tokyo, Japan). The scan rate was set at1OC/min. The phase
transition temperature was determined as the peak temperature.
2.4. Fluorescenceanisotropymeasurement
   The DPPC bilayer was labeled with DPH by adding 10 pL of 10 mM freshly prepared
DPH stock solution in tetrahydrofuran to 1000 pL of liposome suspension and then
incubating at 37 OC for 2 h in the dark to complete the labeling. The treatment with fatty
acids in DPH-labeled liposomes was performed as described above. The pellets were
collected by centrifugation at 13,400xg for 2 min. The obtained pellets were resuspended in
PBS and the absorbance at 400 nm was set ÅqO.50 to permit the measurement of fluorescence.
The fluorescence anisotropy of DPH in the DPPC bilayer was measured with a fluorescence
spectrophotometer (Hitachi F-450, Hitachi Co. Ltd., Tokyo, Japan) at an excitation
wavelength of351 nm and an emission wavelength of430 mn. The steady-state fluorescent
anisotropy was calculated using the following equation:
                               Ivv - IvH
                           r=
                               Ivv + 2IvH
where r is anisotropy, and Ivu and IuH are the intensity measured in directions parallel and
-
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perpendicular to the polarized exciting light, respectively.
2.5. Detergentresistancestudies
   After application of fatty acids to the DPPC liposome suspension, 750 pL of 1O O/o Triton
X-1OO solution was added to 1250 pL ofa DPPC liposome suspension treated with fatty acid,
and the sample was incubated at 25 OC for 2 h. The sample was centrifuged at 13,400xg for
2 min to separate the supernatant and pellet. The supernatant was removed, and the pellets
were resuspended in an equal volume of fresh PBS. The sample was further diluted 100
times with PBS and the optical density (OD) at 400 nm was measured using a
spectrophotometer (U-best 30, Japan Spectroscopic Co., Ltd., Tokyo, Japan). The OD at
400 nm of a freshly prepared DPPC liposome suspension was also measured and this value
was used as the initial level. Detergent insolubility was calculated as the OD after the
addition of Triton X-1OO divided by the initial level.
2.6. Determination of the composition of fatty acids in DPPC bilayer treated with fatty
acids
    Application of unsaturated fatty acids to DPPC liposomes was performed using fatty acid
suspensions. The treatment amount ofeach fatty acid was fixed at 30 molO/o relative to the
amount of DPPC. The pellets were collected by centrifugation at 13,400xg for 2 min and
the pellets were resuspended in an equal volume of fresh PBS. DPPC and fatty acid
concentration were determined using a phospholipidC-Test kit and a NEFA C-Test kit, and
the composition of fatty acids in DPPC bilayer was calculated.
-
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3. ResultsandDiscussion
3.1. Changes in the physical properties of the DPPC bilayer induced by treatment with
fatty acids
   Figure 13 shows the DSC curves of the DPPC bilayer treated with various fatty acids.
For the DPPC bilayer treated with the mixture of PBS and methanol (control), the sharp
endothermic peak due to the phase transition from the gel phase to the liquid-crystalline
phase was observed at 40.8 OC. This temperature is lower than the phase transition
temperature of pure DPPC reported by other researchers (6i'66), and the reduction in phase
transition temperature occurred probably because of the effect of methanol in the treatment
solution. Tran et al. reported a similar effect induced by ethanol (67). In addition, it had
been already confirmed in a preliminary study that DPPC liposomes without any treatment
(blank) had a phase transition at about 42 OC (data not shown). Treatment with unsaturated
fatty acids, such as OA, EPA, and DHA, shifted the phase transition temperature to a lower
value and broadened the sharp endothermic peak (Fig. 13). The phase transition
temperatures of the DPPC bilayer treated with 30 molO/o of fatty acids were 41.3 OC for SA,
37.5 OC for OA, 36.3 OC for EPA, and 36.2 OC for DHA.
    Figure 14 shows the effects of fatty acids (30 molO/o) on the fluorescence anisotropy of
DPH in the DPPC bilayer. Treatment with unsaturated fatty acids shifted the phase
transition of the DPPC bilayer to a lower temperature and broadened the phase transitions
compared with those of the control. These results were consistent with those obtained from
the DSC study (Fig. 13). Treatment with unsaturated fatty acids markedly decreased the
values of fluorescence anisotropy of DPH in the gel phase.
-
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Figure l3. Differential scanning calorimetry thermograms of the DPPC bilayer after
treatment with fatty acids. Thirty mol percent offatty acid relative to the amount ofDPPC
was applied to the DPPC bilayer in the form ofa suspension. The temperature was scanned
at1OCImin. (a) control, (b) SA, (c) OA, (d) EPA, and (e) DHA.
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Figure 14. Fluorescence anisotropy of DPH in the DPPC bilayer after treatment with fatty
acids. Thirty mol percent of fatty acids relative to the amount of DPPC was applied to the
DPPC bilayer in the form of a suspension. The temperature was scanned at 1 OC/min.
Key: (e) control, (A) SA, (i) OA, (o) EPA, and (D) DHA.
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   Furthermore, this study was investigated the effects of the amount of fatty acids used in
the treatment on the phase transition temperature and fluorescence anisotropy of DPH.
Increasing the molar fraction of unsaturated fatty acids induced a notable progressive
decrease in the phase transition temperatures and the values of fluorescence anisotropy of
DPH (Figs. 15 and 16). The modifications induced by DHA and EPA were most
pronounced. These changes are caused by the interaction between fatty acids and the DPPC
bilayer. DPPC, which has two 16-carbon saturated chains, forms a substantially more
tightly packed lipid bilayer. Once applied to the DPPC bilayer, unsaturated fatty acids are
taken up into the lipid bilayer in a dose-dependent manner, reducing the van der Waals
interactions between the phospholipid hydrocarbon chains because of their kinked structure
(29). The decreases in the phase transition temperature and the value of fluorescence
anisotropy reflect this mechanism. Conversely, SA treatment caused a slight increase in the
phase transition temperature and the values of fluorescence anisotropy of DPH (Figs. 15 and
16).
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Figure 15. Effect ofthe treatment amount of fatty acids on the phase transition temperature of
the DPPC bilayer. An adequate amount of fatty acids was applied to the DPPC bilayer in
the form of a suspension. Each value represents the mean Å} S.D. of three experiments.
Key: (e) SA, (A) OA, (i) EPA, and (") DHA.
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Figure 16. Effect ofthe treatment amount of fatty acids on fluorescence anisotropy ofDPH in
the DPPC bilayer at 37 OC. An adequate amount of fatty acids was applied to the DPPC
bilayer in the form of a suspension. Each value represents the mean Å} S.D. of three
experiments. Key: (e) SA, (A) OA, (-) EPA, and (") DHA.
Because SA is a saturated fatty acid composed of a longer hydrocarbon chain than DPPC, the
packing of the DPPC bilayer might be tighter after treatment with SA. The detergent
insolubility ofthe DPPC bilayer treated with fatty acids was also assessed. This method is
based on the observation that ordered lipid domains tend to resist solubilization by nonionic
detergents, such as Triton X-100, whereas disordered fluid domains dissolve in these
detergents. The insoluble membrane fraction can be regarded as tightly packed domains
that were present in the sample before the addition of detergent. London et al. used
detergent insolubility as an index of the formation of ordered lipid domains (lipid raft) in a
model lipid bilayer (68'69). It was found that fatty acid treatment influenced the distribution
of the ordered lipid domain in the membrane. Table 6 shows the detergent insolubility of
the DPPC bilayer treated with 30 molO/o of fatty acids. Considerable amounts of insoluble
membrane fractions were obtained from the control and SA treatment conditions (Table 6),
indicating that these membranes were composed of a large amount of ordered and rigid
-
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regions. In contrast, the DPPC bilayer treated with unsaturated fatty acids was nearly
completely dissolved in Triton X-100. The lowest level of detergent insolubility was
observed with DHA and EPA treatment, suggesting that the tightly packed membrane of the
DPPC bilayer was altered in the disordered fiuid membrane by treatment with unsaturated
fatty acids, particularly DHA and EPA.
            Table 6. Detergent insolubility of the DPPC bilayer after
            treatment with fatty acids
    Detergent insolubility
(OD4oonm+TX-1OO)1(OD4oonm-TX-1OO)
Controla
SA
OA
EPA
DHA
O.501 Å} O.027
O.612 Å} O.O16
O.092 Å} O.O06
O.030 Å} O.O02
O.030 Å} O.O04
aMixture ofPBS and methanol (1:1 vlv O/o)
Thirty mol percent of fatty acids relative to the amount of
DPPC was applied to the DPPC bilayer in the form of a
suspension. Each value represents the mean Å} S.D. of three
determinations.
TX•-1OO, Triton X-1OO.
   These results confirmed that the unsaturated fatty acids changed the lipid bilayer
structure markedly. The modifications of the bilayer physical properties were more
pronounced with DHA and EPA than with OA treatment. The order of potency of the
modifications of the physical properties induced by unsaturated fatty acids agreed with the
order oftheir absorption enhancement effect observed in Chapter 1. It is speculated that the
potency of the modifications depends on the molecular structure and amount of fatty acids
incorporated into the lipid bilayer. To examine the possible mechanism responsible for the
differences in potency, the composition of fatty acids in the DPPC bilayer after incubation
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with unsaturated fatty acids was determined. As shown in Table 7, each fatty acid
comprised over 25 molO/o of the bilayer lipid component, and the relative composition was
nearly identical for all fatty acids tested. This finding indicates that the different actions of
the various unsaturated fatty acids can be attributed mainly to changes in the bilayer
molecular structure, such as a kinked conformation contributed by the double bond, and not
to the amount of fatty acids incorporated into the lipid bilayer.
  Table 7. Composition of fatty acids in the DPPC bilayer after treatment with
  unsaturated fatty acids
Fatty acid
 (molO/o)
DPPC
(molO/o)
OA
EPA
DHA
27.0 Å} O.3
26.4 Å} O.4
25.9 Å} O.2
73.0 Å} O.3
73.6 Å} O.4
74.1 Å} O.2
Thirty mol percent of fatty acids relative to the amount of DPPC was applied to the
DPPC bilayer in the form ofa suspension. Each value represents the mean Å} S.D. of
three determinations.
3.2. Effect of fatty acids contained in W/OIW multiple emulsions on membrane fluidity
    Figure 17 shows the DSC curves ofthe DPPC bilayer treated with emulsions containing
various fatty acids. A sharp endothermic peak was observed at about 42 OC, and a broad
endothermic peak also obtained at below 40 OC in the DPPC bilayer treated with the emulsion
without fatty acid (control). The sharp endothermic peak reflects the phase transition of
pure DPPC domains and the broad endothermic peak reflects the disordered fluid domains
that were altered by the treatment with emulsion in the membrane. The emulsion in itself
induced a marked change in the lipid bilayer structure because the emulsion contains large
amounts of unsaturated lipids, such as triolein and egg yolk phospholipids. The
endothermic peak at about 42 OC decreased after treatment with the emulsion containing OA
and disappeared completely after treatment with the emulsion containing DHA or EPA.
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Figure 17. Differential scanning calorimetry thermograms of the DPPC bilayer after
treatment with a WIOIW multiple emulsion. Emulsion containing 2 O/o fatty acid was
applied to the DPPC bilayer. The temperature was scanned at 1 OCImin. (a) control, (b) SA,
(c) OA, (d) EPA, and (e) DHA.
Table 8 lists the fluorescence anisotropy values of DPH in the bilayer treated with the
emulsions at 37 OC. These values decreased markedly with treatment with emulsion
containing unsaturated fatty acids. Table 9 summarizes the detergent insolubility values of
the DPPC bilayer treated with emulsion. A large amount of DPPC was dissolved in Triton
X-100 in all samples, which showed only very low levels of insolubility. These results
demonstrate that unsaturated fatty acids act efficiently on the DPPC bilayer, even when
included in emulsion form, which obviously changed the physical properties of the DPPC
bilayer.
-
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Table 8. Fluorescence anisotropy of DPH in the DPPC bilayer
after treatment with WIOIW multiple emulsions containing
fatty acids at 37 OC
Fluorescence
 amsotropy
Controla
SA
OA
EPA
DHA
O.305
O.346
0278
O.208
O.210
Å}
Å}
Å}
Å}
Å}
O.O07
O.O02
O.O05
O.O06
O.O05
aW!OIW multiple emulsion without fatty acids
Each value represents the mean Å} S.D. ofthree determinations.
Table 9.
treatment
acids
Detergent insolubility
with W!OIW multiple
of the DPPC bilayer
emulsions containing
after
fatty
    Detergent insolubility
(OD4oonm+TX-1OO)1(OD4oonm-TX-1OO)
Controla
SA
OA
EPA
DHA
O.045
O.101
O.O12
O.O07
O.O08
Å}
Å}
Å}
Å}
Å}
O.O02
O.030
O.O05
O.O03
O.O08
aWIOIW multiple emulsion without fatty acids
Each value represents the mean Å} S.D. ofthree determinations.
TX-1OO, Triton X-1OO.
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4. Conclusions
   The structural changes in a DPPC bilayer induced by treatment with various fatty acids
were clarified by determining the phase transition temperature, fiuorescence anisotropy of
DPH, and detergent insolubility. Treatment with unsaturated fatty acid broadened and
shifted the phase transitions of the DPPC bilayer to a lower temperature. The phase
transition temperature and the value of fluorescence anisotropy of DPH at 37 OC decreased
progressively with increasing treatment amounts of unsaturated fatty acid. A large amount
of the DPPC bilayer treated with unsaturated fatty acid was dissolved in Triton X-100,
yielding a low level of detergent insolubility. These modifications of the bilayer physical
properties were most pronounced with DHA and EPA treatment. These results show that
unsaturated fatty acids, particularly DHA and EPA, induce a marked change in the lipid
bilayer structure. The composition of fatty acids in the DPPC bilayer was similar after
treatment with various unsaturated fatty acids, suggesting that the different actions of
unsaturated fatty acids are attributed to change in the molecular structure (e.g., kinked
conformation by double bonds). This study further explored the change in physical
properties induced by fatty acids dispersed in the W/OIW multiple emulsion and found that
unsaturated fatty acids acted efficiently on the DPPC bilayer, even when incorporated in the
emulsion form.
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                      CHAPTER3
Formulation optimization of VV/O/W multiple emulsion as a carrier of
insulin intestinal delivery according to a novel optimization technique
-
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1. Introduction
   Chapters 1 and 2 investigated the feasibility of unsaturated fatty acids as absorption
enhancers for intestinal insulin absorption. It was clarified that unsaturated fatty acids,
especially DHA, possessed the great activity for promoting insulin absorption, and it was
related to the structural change in lipid bilayer. This chapter focuses on the formulation
design of WIOIW multiple emulsion using a novel optimization technique. In general,
pharmaceutical formulations are composed ofmany components and undergo manufacturing
processes, and numerous factors are involved in generating their various characteristics.
Since the relationships between the factors and characteristics are complex, undesirable
formulations are sometimes obtained. Therefore, it is important to identify the
relationships between the causal factors and individual characteristics, and to optimize these
variables for the formulation's purpose. The WIOIW multiple emulsion is also a complex
system, including many components and manufacturing processes. Although the
absorption enhancer must play a principal role in the pharmacological effect, other causal
factors may exist, because there are several reports that numerous factors influenced the
pharmacological effect ofthe final formulation (70'7i). In addition to the pharmacological
effect, many characteristics should be considered in the design of pharmaceutical
formulations. The stability of the resulting formulation is an important characteristic,
because its appearance and homogeneity should be preserved during long-term storage.
Physical properties are also important characteristics because they may affect crucial
characteristics, such as the pharmacological effect and stability, although their optimum
values are not always required (72-74).
    The objective of this study was to identify the relationships between the forrnulation
factors and characteristics, and optimize the formulation of the emulsion for mucosal insulin
delivery. Firstly, model formulations were prepared according to the L16 orthogonal
t 43-
experimental design. OA was used as an absorption enhancer in this study. Response
variables, such as the inner droplet size, viscosity, stability and hypoglycemic effect, were
measured, and then the contributions of the causal factors and their interactions to response
variables were clarified by means of ANOVA analysis. The orthogonal experimental
design is known to be an efficient method to clarify the relationship of multivariate data
(75-77). Furthermore, the formulation optimization of W/OIW multiple emulsion was
performed by means of a computer optimization technique incorporating a multivariate
spline interpolation (Mvs) (78779).
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2. MaterialsandMethods
2.1. Materials
   Gelatin, triolein, Span 80, Tween 80, DL-ct-tocopherol, egg yolk phospholipids
(phosphatidylcholine and phosphatidylethanolamine) and OA were the same as those
described in Chapter 1 and 2. Crystalline porcine insulin (27.3 IUImg) was purchased from
Wako Pure Chemical Industries, Ltd. (Osaka, Japan). All other chemicals were of
analytical grade.
2.2. PreparationofVV/O/VVmultipleemulsion
   The emulsions were prepared according to the method described in previous Chapters.
The L16 orthogonal experimental design for five factors and the two-factor spherical
second-order composite experimental design were applied to prepare the model formulations.
The preparation conditions of model formulations are listed in Tables 10 and 11. For the
orthogonal experimental design, the gelatin concentration in inner aqueous phase, insulin
amount in 2g of inner aqueous phase, volume ratio ofouter aqueous phase to the total, OA
concentration in WIOIW multiple emulsion and agitation time of the second emulsification
process were selected as the causal factors. For the composite spherical experimental
design, the ratio of the outer aqueous phase to the total volume and agitation time of the
second emulsification process were selected as the causal factors.
-
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Table 10. Formulations for insulin emulsi on based on orthogonal experimental design
Formulation
  number
  A
Gelatin
 (o/o)
  B
Insulin
(Unit)
    C
Outer aqueous
 phase (O/e)
   D
OIeic acid
  (o/o)
   F
Agitation
time (min)
Rp. 1
Rp.2
Rp. 3
Rp.4
Rp.5
Rp.6
Rp.7
Rp.8
Rp.9
Rp. 10
Rp. 11
Rp. 12
Rp. 13
Rp. 14
Rp. 15
Rp. 16
o
o
o
o
o
o
o
o
10
10
10
10
10
10
10
10
200
200
200
200
600
600
600
600
200
200
200
200
600
600
600
600
66.7
66.7
85.7
85.7
66.7
66.7
85.7
85.7
66.7
66.7
85.7
85.7
66.7
66.7
85.7
85.7
o
5
o
5
o
5
o
5
o
5
o
5
o
5
o
5
2
5
5
2
5
2
2
5
5
2
2
5
2
5
5
2
Table 11. Formulations for insulin
experimental design for two factors
emulsion based on composlte spherical
Formulation
 number
Xia X2a Outer aqueous
 phase (o/,)b
Agitation time
   (min)b
Rp. 1
Rp.2
Rp.3
Rp.4
Rp. 5
Rp.6
Rp.7
Rp.8
Rp.9
Rp. 10
-
1
 -1
  1
  1
- jj
 o
 o
 o
 o
 -1
 1
 -1
 1
 o
 o
- jj
 o
 o
62.9
62.9
77.1
77.1
60.0
80.0
70.0
70.0
70.0
70.0
2.44
4.56
2.44
4.56
3.50
3.50
2.00
5.00
3.50
350
aCoded form, bphysical units.
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2.3. Dropletsizemeasurement
   The size ofthe inner droplets ofthe emulsion was measured in freshly prepared samples.
The mean diameter of the emulsion was determined using a dynamic laser light scattering
instrument (ELS-800, Otsuka Electronics Co., Ltd., Osaka, Japan). The emulsion was
diluted (approximately 500 times) with purified water before the measurement.
2.4. Viscositymeasurement
   The viscosity measurement ofthe fresh emulsion was canied out using a cone and plate
type rheometer (Rheomat 15, Contraves Industrial Products Ltd., Middlwsex, UK) at 25 OC
and a shear rate of 7.8 s'i.
2.5. Stabilityoftheemulsions
   The stability of the emulsions was evaluated by a turbidity measurement method to
determine the phase separation described by Pearce and Kinsella (80). In the turbidity
measurement method, the emulsion was packed into a syringe (1 mL volume) immediately
after preparation and was stored standing vertically at 4 OC. Samples were taken from the
lower side of the syringe at O, 1, 3, 5 and 10 days after preparation, diluted 100 times with
purified water, and then the turbidity was measured using a spectrophotometer (Ubest-30,
Japan Spectroscopic Co., Ltd., Tokyo, Japan) at 600 nm. A decrease in the homogeneity of
the emulsion (i.e., a decrease in the emulsion stability) was expressed as a percentage ofthe
initial value of the turbidity The extent of the stability response of the emulsion was
calculated as the area above the curve of the percentage change in the turbidity levels
(AACturbidity) for O-1O days using the trapezoidal method.
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2.6. In vivo insulin absorption experiments
   Male Wistar rats weighing 180-200 g were purchased from the Sankyo Lab Service Co.
Ltd. (Tokyo, Japan). The rats were fasted for 48 h prior to the experiments. Following
anesthetization with the i.p. injection of sodium pentobarbital (50 mglkg), the rats were
restrained in a supine position on a thermostatically controlled board at 37 OC. Then,
insulin emulsions were administered directly into the rectum. Insulin doses were changed
by adjusting the emulsion amount. In the orthogonal experimental design study and the
OA's dose-dependency study, the insulin doses were fixed at 10 and 20 IUIkg of body
weight, respectively. Blood samples (O.1 mL) were withdrawn from the jugular vein at 5
min prior to administration and O.5, 1, 2, 3 and 4 h following administration. Blood
glucose levels were determined using a Novo Assist@ Plus (Novo Nordisk Pharma., Ltd.,
Tokyo, Japan). The post-dose serum glucose levels were expressed as a percentage of the
pre-dose levels. The hypoglycemic response was evaluated using AACgiucose, calculated
from the time curve of the blood glucose levels, similar to the stability study. The mean
values and standard deviations were calculated from five rats.
2.7. Dataanalysis
   Results of the L16 orthogonal experimental design for five causal factors were
statistically analyzed based on the ANOVA technique using a computer program,
STATISTICA (Statsoft, Tulsa, OK, USA). As for the optimization study, the optimum
formulation was estimated using a simultaneous optimization technique, in which MVS was
incorporated. A two-factor composite second-order spherical experimental design was
employed to select the model formulation. The data measured for the model formulations
were analyzed with a computer program, dataNESIA (Yamatake Corp., Tokyo, Japan). The
MVS has recently been recognized as a superior method for the high precision modeling of
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multi-dimensional data points (8i). MVS is basically a boundary element method (82).
Green functions are used for interpolating the minimum curvature ofmulti-dimensional data
points (82). As usual, observational data include experimental error. To avoid the problem
of over estimation, the multi-dimensional data surface, including the experimental error, is
estimated as the sum of interpolation with a Green function in a linear polynomial equation
(thin-plate approximation) (83). The smoothing parameter, which is the ratio of the Green
function interpolation and thin-plate approximation, is automatically estimated using a
generalized cross-validation technique. The optimum formulation was estimated based on
the standardized Euclidian distance described previously (84).
-
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3. Results and Discussion
3.1. ANOVAanalysis
   Owing to ANOVA analysis, the relationships between the formulation factors and
characteristics were clarified. The experimental values ofeach response variable are listed
in Table 12, and ANOVA tables for the individual characteristics are shown in Tables 13-16.
As shown in Table 13, the volume ratio of the outer aqueous phase significantly affected the
diameter of the inner droplet (i.e., W!O emulsion dispersed in the outer aqueous phase), and
its contribution index was 20.3 O/o (Table 13). The decrease in the volume ratio ofthe outer
aqueous phase resulted in the increase in the diameter ofinner droplet. This was probably
due to the aggregation of inner droplets. Span 80 and Tween 80, the non-ionic surfactants
contained in emulsion as emulsifiers, locate at the interface of the oily phase and outer
aqueous phase, respectively. These surfactants can interact with each other via van der
Waals forces. This interaction contributes to the strength of the interfacial film and
stabilizes the emulsion system against particle coalescence. The dispersion of inner
droplets in the outer aqueous phase occurs due to the interaction between Span 80 and
Tween 80 (85). When the density of the inner droplet in the continuous phase is going to
increase, inner droplets are allowed to interact with each other, resulting in the formation of
aggregates all over the emulsion. The aggregation is reversible and the aggregates can be
broken down by gentle shaking, since the van der Waals force is a very weak interaction.
In fact, preliminary experiments showed that the viscosity of emulsions composed of a
lower volume of outer aqueous phase decreased with the prolongation of the agitation time,
or the increase in the shear rate, indicating that they were thixotropic fluids, while the
viscosity of emulsions possessing a higher volume of the outer aqueous phase did not show
any change (data not shown). These changes in viscosity strongly support the hypothesis.
    In contrast to the droplet size, various factors and their interactions affected the
-
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viscosity ofthe emulsion significantly (Table 14). The viscosity ofthe emulsion increased
with the increase in the gelatin concentration in the inner aqueous phase, the decrease in the
volume ratio of the outer aqueous phase and the OA amount, and the shortening of the
agitation time. Among all of these factors, the volume ratio of the outer aqueous phase's
contribution was clearly the most predominant, and all of the interactions significantly
affected the viscosity ofthe emulsion. At a lower volume ofouter aqueous phase, the inner
droplets aggregated with each other via a low binding force, the van der Waals force, and
they formed a network structure in the sample. In addition, the oily phase is obviously
more viscous than the aqueous phase. Therefore, the physical interactions ofinner droplets
and the stickiness of the oily phase resulted in the high viscosity. The gelatin solution is
much more viscous, so it is reasonable that the viscosity of the emulsion was increased by
the addition of gelatin to the inner aqueous phase. The decrease in the amount of OA in the
oily phase indicates the increase in the amount of triolein, because it is the component to
adjust the weight ofthe oily phase. Since the molecular weight oftriolein is approximately
three times greater than that of OA, triolein is much more viscous than OA. Thus, the
change in the composition of the emulsion caused the increase in its viscosity. In addition,
the viscosity of the emulsion increased with the shortening of the agitation time.
Considering the high shear stress caused by the homogenizer, it is thought that the agitation
process greatly affected the forming emulsion and then changed the rheological property of
the final products.
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Table 12. Experimental values of response variables of insulin emulsion prepared according to
orthogonal design
Formulation
number
Droplet size
 (nm)
Viscosity
(mPa•s)
 Turbidity
AACturbidity (O/o reduc.' day)
Hypoglycemic effect
AACgi.co,, (O/o glu. reduc.' h)
Rp. 1
Rp.2
Rp.3
Rp.4
Rp.5
Rp.6
Rp.7
Rp.8
Rp.9
Rp. 10
Rp. 11
Rp. 12
Rp. 13
Rp. 14
Rp. 15
Rp. 16
455.6 Å} 123.1
492.6 Å} 93.4
262.8 Å} 18.5
287.5 Å} 51.4
590.5 Å} 209.1
397.4 Å} 112.2
409.0 Å} 73.9
347.9 Å} 33.4
377.7 Å} 59.1
316.0 Å} 34.8
338.3 Å} 27.0
273.9 Å} 62.1
539.2 Å} 91.5
334.0 Å} 64.9
263.1 Å} 9.4
410.9 Å} 143.3
36.6
6.9
5.2
6.8
14.1
34.3
9.9
5.7
29.4
38.6
8.9
5.4
76.0
22.2
6.3
6.0
47.4 Å} 41.7
680.4 Å} 13.0
600.3 Å} 25.4
762.1 Å} 11.2
634.3 Å} 14.7
484.5 Å} 48.6
776.6 Å} 14.6
766.6 Å} 10.1
370.0 Å} 103.6
531.2 Å} 101.2
768.1 Å} 3.8
594.2 Å} 6.5
22.5 Å} 19.7
661.0 Å} 15.3
606.9 Å} 17.4
783.8 Å} 5.4
24.2
42.4
26.3
48.4
18.0
50.2
2.5
39.7
34.3
57.7
41.8
57.1
O.9
82.5
31.4
83.4
Å} 25.9
Å} 19.2
Å} 36.7
Å} 40.3
Å} 14.6
Å} 36.3
Å} 4.3
Å} 43.6
Å} 22.6
Å} 30.8
Å} 25.1
Å} 26.4
Å} 1.9
Å} 40.4
Å} 20.6
Å} 51.6
Each value represents the mean Å} S.D.
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Table 13. ANOVA table for
orthogonal design
inner droplet size of insulin emulsion prepared according to
Factor DFa Msb Foc Contribution
  index
A
B
C
D
F
A*B
A*C
A*D
A*F
B*C
B*D
B*F
C*D
C*F
D*F
Error
Total
(Gelatin)
(Insulin)
(Outer aqueous phase)
(Oleic acid)
(Agitation time)
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
16
32
 19035.4
29723.5
103445.4
 17687.5
 5593.8
    3.2
 15155.0
   1O.9
 31244.4
  303.4
 7634.5
 6637.0
 27603.7
 18505.5
 10132.8
 103518
1.8
2.9
   **10.0
1.7
O.5
o.o
1.5
o.o
3.0
o.o
O.7
O.6
2.7
1.8
1.0
  1.9
 4.2
20.3
  1.6
 o.o
 o.o
  1.1
 o.o
 4.6
 o.o
 o.o
 o.o
 3.8
  1.8
 o.o
60.8
100.0
aDegrees of freedom, bMean square, CObserved F value.
**
 p Åq O.Ol
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Table 14. ANOVA
orthogonal design
table for viscosity of insulin emulsion prepared according to
Factor DFa Msb Foc Contribution
   index
A
B
C
D
F
A*B
A*C
A*D
A*F
B*C
B*D
B*F
C*D
C*F
D*F
Error
Total
(Gelatin)
(Insulin)
(Outer aqueous phase)
(Oleic acid)
(Agitation time)
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
16
32
 669.8
 168.4
5191.8
 460.6
1857.5
  48.0
 708.8
 1638
  14.0
 139.5
  30.0
 143.7
 285.6
1346.8
 119.4
  43.0
    **
 15.6
  3.9
    **120.6
    **
 10.7
    **432
  IJ
    **
 16.5
  3.8
  O.3
  3.2
  O.7
  3.3
    *
  6.6
    **
 31.3
  2.8
  5.2
  1.0
 42.8
  3.5
 15.1
 o.o
  5.5
  1.0
 o.o
 O.8
 o.o
 O.8
 2.0
 10.8
 O.6
 10.7
100.0
aDegrees of freedom, bMean square, CObserved F value.
*
        **pÅqO.05, pÅqO.Ol
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    With respect to final products, one of the most important considerations is stability.
Stability of this emulsion system is characterized by an absence of coalescence of the
internal phase, an absence of creaming, and maintaining its elegance in terms of appearance,
such as odor, color and other physical properties. The stability of the emulsion was
evaluated from the AACturbidity values calculated by the turbidity change-time curve, which
expressed the extent of the turbidity decrease, and a stable emulsion was defined as one
having a low AACturbidity value. As shown in Table 15, the stability ofthe emulsion was
significantly influenced by all the causal factors. The stability of the emulsion.increased
with the increase in the gelatin concentration, the decrease in the insulin, the OA amount and
the volume ratio ofthe outer aqueous phase, and the shortening ofthe agitation time. The
effect of the gelatin contained in the inner aqueous phase on the stability of the emulsion
systems was found in our previous study (23). As well as the droplet size and viscosity, the
most significant factor affecting the stability of the emulsion is the volume ratio of the outer
aqueous phase (Table 13). The network formations ofthe inner droplets via van der Waals
forces decrease the dynamic activity of themselves, resulting in the stabilization of the
emulsion. Moreover, the ANOVA analysis suggested some relationship between the
viscosity and the stability of the emulsion, since the preparation conditions for a viscous
emulsion were very much similar to that required for a stable emulsion.
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Table 15. ANOVA
orthogonal design
table for stability of insulin emulsion prepared according to
Factor DFa Msb Foc Contribution
   index
A
B
C
D
F
A*B
A*C
A*D
A*F
B*C
B*D
B*F
C*D
C*F
D*F
Error
Total
(Gelatin)
(Insulin)
(Outer aqueous phase)
(Oleic acid)
(Agitation time)
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
32
48
 32209.2
 27427.7
930134.5
387684.8
101954.8
1085852
  2244.1
  5271.0
 44032.0
   238.5
  3005.2
 40565.5
238600.2
595900.8
 39045.0
  1721.3
    **
 18.7
    **
 15.9
    **540.4
    **225.2
    **
 59.2
    **
 63.1
  1.3
  3.1
    **
 25.6
 O.1
  1.8
    **
 23.6
    **138.6
    **346.2
    **22.7
  1.2
  1.0
 35.5
 14.8
  3.8
 4.1
  o.o
  O.1
  1.6
  o.o
  O.1
  1.5
  9.1
 22.8
  1.4
  3.0
100.0
aDegrees of freedom, bMean square, CObserved F value.
**
 p Åq O.Ol
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   In the insulin absorption study, the addition of gelatin and OA significantly increased
the insulin's pharmacological effect (Table 16). A previous study demonstrated that a
gelatin free emulsion did not induce any hypoglycemic effect following ileal administration
(23). The high viscosity surrounding insulin molecules can protect the insulin degradation
from enzymatic hydrolysis and prolong the residence time of insulin at the mucosal
membrane. The contribution of OA to the pharmacological effect of the emulsion was
outstanding, its contribution index being 23.4 O/o (Table 16). The pharmacological effect of
the insulin emulsion was strongly affected by the absorption enhancement effect of the OA
rather than by the physical properties ofthe emulsion, such as the viscosity or droplet size.
-
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Table 16. ANOVA table for
to orthogonal design
hypoglycemic effect of insulin emulsion prepared according
Factor DFa Msb Foc Contribution
   index
A
B
C
D
F
A*B
A*C
A*D
A*F
B*C
B*D
B*F
C*D
C*F
D*F
Error
Total
(Gelatin)
(Insulin)
(Outer aqueous phase)
(Oleic acid)
(Agitation time)
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
64
80
 5875.8
  175.3
  130.1
24824.8
  159.5
  454.0
  982.5
 1225.5
  130.9
   28.0
 4818.8
  681.1
  260.0
 1354.6
 1079.5
  935.1
   *
 6.3
O.2
O.1
   **26.6
O.2
O.5
 1.1
 1.3
O.1
o.o
   *
 5.2
O.7
O.3
 1.5
 1.2
 4.8
 o.o
 o.o
23.4
 o.o
 o.o
 O.1
 O.3
 o.o
 o.o
 3.8
 o.o
 o.o
 O.4
 O.1
 67.1
100.0
aDegrees of freedom, bMean square, CObserved F value.
*
        **pÅqO.05, pÅqO.Ol
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3.2. Formulationoptimization
   Based on the results of the orthogonal experimental design study, the optimum
formulation of the emulsion, which had both a high pharmacological activity and stability as
a pharmaceutical formulation, was estimated. To begin with, the OA concentration in the
emulsion was determined by the consideration of its pharmacological effect and toxicity.
As shown in Fig. 18, the hypoglycemic effects increased with the increase in the OA
concentration in the range of O to 2 O/o of the emulsion. Particularly, a marked
pharmacological effect was induced at an OA concentration of 2 O/o. Furthermore, it had
been confirmed that no mucosal damage is induced by the multiple applications of insulin
emulsion containing 2 O/o OA in Chapter 1. Therefore, the optimal OA concentration was
decided at 2 O/o. Subsequently, model formulations were prepared according to the
two-factor spherical second-order composite experimental design (Table 11), and their
stability was determined. The volume ratio of the outer aqueous phase and the agitation
time were selected as the causal factors, since these contributions to stability were very large,
approximately 62.1 O/o in total, including their interactions (Table 15). The other variable
factors were fixed as follows: OA, 2 O/o of total weight; gelatin, 5 O/o of the inner aqueous
phase; insulin, 200 IU per 2 g ofthe inner aqueous phase. A three-dimensional diagram of
the stability as a function of the volume ratio of the outer aqueous phase, and the agitation
time is shown in Fig. 19. Nonlinear relationships between the causal factors and the
response variables were represented by the response surface, as predicted by MVS (Fig. 19).
With the decrease in the fraction of the outer aqueous phase and the shortening of the
agitation time, the AACturbidity values decreased, resulting in the increased stability of the
emulsion.
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Figure 18. Comparison of hypoglycemic efifects of insulin emulsion incorporating various
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   Finally, the optimal formulation was estimated and evaluated. The values ofthe causal
factors that give the minimal AACt.,bidity value are listed in Table 17. Since the
experimental value of AACturbidity was almost zero, it was concluded that the predicted
values were in agreement with the experimental values, and the formulation was thought to
be highly stable. Thus, the optimum formulation, having a desirable pharmacological
effect and high stability, was successfu11y obtained.
Table 17. 0ptimal formulation composition of insulin emulsion predicted by MVS and
predicted and observed values of stability
Factor Response
Outer aqueous phase
       (o/o)
Agitation time
   (min)
/VXCturbidity (O/o reduc.• day)
Predicted value Observed valuea
60.7 2.97 o.o 15Å}1.6
aMean Å} S.D. of three determinations.
-
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4. Conclusions
   ANOVA analysis revealed the relationships between the formulation factors and the
individual characteristics. The droplet size ofthe emulsion increased significantly with the
decrease in the volume ratio ofthe outer aqueous phase to the total. Both the viscosity and
the stability of the emulsion were affected by various causal factors and their interactions,
and it was suggested that they had something to do with each other. As for the
hypoglycemic effect, the most influential factor was the arnount of OA, which was used as
an absorption enhancer to the emulsion. Based on the response surface generated by MVS,
the optimum formulation, having the highest stability and the most desirable
pharmacological effect, was successfully prepared.
-
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SUMMARY
   Insulin is a key hormone regulating the blood glucose level, and it is the mainstay of
drug therapy for patients with insulin-dependent diabetes mellitus. All current insulin
preparations are limited to the injection dosage form, so an alternative route, especially an
oral route, of insulin delivery has been desired for a long time. However, it is diffricult to
deliver insulin via the gastrointestinal tract because of extensive proteolytic degradation by
intestinal enzymes and insufficient membrane permeability due to its high molecular weight
and low lipophilicity.
   A WIOIW multiple emulsion is thought to be an efficient drug canier because it can
protect peptides and incorporate various types of absorption enhancers in each phase, in
accordance with its solubility. In addition, PUFAs are well known functional lipids that
possess various biological actions, and they are expected to be effective absorption enhancers
for intestinal insulin delivery. The aim of this study was to establish a novel insulin enteral
delivery system using a WIOIW multiple emulsion containing PUFAs.
    In Chapter 1, the enhancement effect on intestinal insulin absorption and the mucosal
damage induced by PUFAs were evaluated with an in vivo and in situ study. Marked insulin
absorption and a hypoglycemic effect were shown within a very short time after the rectal
administration of insulin emulsion. The hypoglycemic effects were in an insulin dose
related manner. The enhancement effects of PUFAs, in particular DHA, were much more
pronounced than that ofoleic acid, and reached saturation point at 1 O/o ofthe total amount of
emulsion. The effect of DHA was outstanding compared to those of its glyceride forms or
medium chain fatty acids. In addition, the effect ofDHA was site-dependent, and the action
of DHA in the large intestine, such as the colon and rectum, was stronger than that in the
small intestine, such as the ileum. Considering the clinical use of insulin preparations, a
-
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multiple administration study was conducted. During the multiple rectal applications ofthe
insulin emulsion for 10 days, the hypoglycemic effects were successfu11y obtained, and no or
very slight mucosal damage was observed in the excised rectum. Moreover, to manipulate
the glucose reduction profile, a gel formulation that combined the insulin emulsion with
PF127 hydrogel was prepared, and the hypoglycemic eflrect was evaluated. As expected, the
sustained hypoglycemic effect was shown by the administration ofthis gel formulation.
   The structural change in the lipid bilayer is a critical factor for the transcellular pathway.
In Chapter 2, the structural changes in a DPPC bilayer induced by treatment with various
fatty acids were clarified by determining the phase transition temperature, fluorescence
anisotropy of DPH, and detergent insolubility. Treatment with unsaturated fatty acid
broadened and shifted the phase transitions of the DPPC bilayer to a lower temperature.
The phase transition temperature and the value of fluorescence anisotropy of DPH at 37 OC
decreased progressively with increasing treatment amounts of unsaturated fatty acid. A
large amount of the DPPC bilayer treated with unsaturated fatty acid was dissolved in Triton
X-100, yielding a low level of detergent insolubility. These modifications of the bilayer
physical properties were most pronounced with DHA and EPA treatment. These data show
that unsaturated fatty acids, particularly DHA and EPA, induce a marked change in the lipid
bilayer structure. The composition of fatty acids in the DPPC bilayer was similar after
treatment with various unsaturated fatty acids, suggesting that the different actions of
unsaturated fatty acids are attributed to change in the molecular structure (e.g., kinked
conformation by double bonds). This study further explored the change in physical
properties induced by fatty acids dispersed in the WIOIW multiple emulsion and found that
unsaturated fatty acids acted efficiently on the DPPC bilayer, even when incorporated in the
emulsion form.
   Numerous variable factors including components and the manufacturing process may
-
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affect various responses ofpharmaceutical formulations. For the design ofpharmaceutical
formulations, it is important to clarify the relationship between the causal factors and the
individual characteristics, and to optimize these variables simultaneously. The aim of
Chapter 3 was to optimize the formulation of the WIOIW multiple emulsion for intestinal
mucosal insulin delivery. ANOVA analysis revealed the relationships between the
formulation factors and the individual characteristics. The droplet size of the emulsion
increased significantly with the decrease in the volume ratio of the outer aqueous phase to
the total. Both the viscosity and the stability of the emulsion were affected by various
causal factors and their interactions, and it was suggested that they had something to do with
each other. As for the hypoglycemic effect, the most infiuential factor was the amount of
OA, which was used as an absorption enhancer to the emulsion. Based on the response
surface generated by MVS, the optimum formulation, having the highest stability and the
most desirable pharmacological effect, was successfu11y prepared.
    In conclusion, it was found in this study that PUFAs are valuable functional fatty acids
which enable to improve the intestinal insulin absorption without evoking any mucosal
damages. This study also clarified that WIO/W multiple emulsion is useful drug delivery
carrier. Results observed in this study provide great benefits for those researching in oral
delivery ofpeptide drugs.
-
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